Home > Riviste > The Journal of Cardiovascular Surgery > Fascicoli precedenti > The Journal of Cardiovascular Surgery 2017 June;58(3) > The Journal of Cardiovascular Surgery 2017 June;58(3):416-21



Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca


Publication history
Per citare questo articolo



The Journal of Cardiovascular Surgery 2017 June;58(3):416-21

DOI: 10.23736/S0021-9509.17.08303-3


lingua: Inglese

Primary stenting is nowadays the gold standard treatment for TASC II A & B iliac lesions: the definitive MISAGO 1-year results

Koen DELOOSE 1, Marc BOSIERS 1, Joren CALLAERT 1, Jürgen VERBIST 2, Frank VERMASSEN 3, Dierk SCHEINERT 4, Giovanni TORSELLO 5, Patrick PEETERS 2

1 Department of Vascular Surgery, AZ Sint‑Blasius, Dendermonde, Belgium; 2 Department of Cardiovascular and Thoracic Surgery, Imelda Hospital, Bonheiden, Belgium; 3 Department of Thoracic and Vascular Surgery, University Hospital Gent, Gent, Belgium; 4 Department of Angiology, Leipzig Heart Center, Leipzig, Germany; 5 Department of Vascular Surgery, St. Franziskus Hospital and University Hospital of Münster, Münster, Germany


BACKGROUND: The MISAGO ILIAC Study is a prospective, non-randomized, multicenter, bi-national, monitored trial, conducted in 3 hospitals in Belgium and 2 hospitals in Germany. This manuscript reports the findings up to 12-month follow-up time for the total cohort. The primary endpoint of the study was primary patency, defined as a target lesion without a hemodynamically significant stenosis on Duplex ultrasound (>50%, peak systolic velocity ratio no greater than 2.0) and without target lesion revascularization (TLR), within 12 months.
METHODS: Between September 2011 and April 2012, 120 patients with TASC II Class A or TASC II Class B aortoiliac lesions were included. The cumulative lesion length in the overall population was 45.49 mm with a maximum stenosis pre-treatment of 83.76%. The demographic data were compatible for the TASC II class A and TASC II class B cohort. One patient with a TASC II class C was included as a protocol deviation.
RESULTS: The primary patency rate for the total patient population was 97.4%. The primary patency rates at 12 months for the TASC II class A and TASC II class B(C) lesions were respectively 98.3% and 96.6%. No statistical significant difference was shown when comparing these 2 groups (P=0.6407).
CONCLUSIONS: Our findings confirm that nowadays primary stenting with modern generation stents replaced the more invasive surgery as the golden standard treatment for patients with TASC II class A and B aortoiliac lesions.

KEY WORDS: Peripheral arterial disease - Iliac artery - Stents

inizio pagina